Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
105
Sex
Women only
Ages
Ages 45 Years to 59 Years
Primary completion
2024-06-30
Last update
2025-04-30

What this trial studies

Emotional freedom technique will be applied to menopausal women. Emotional freedom technique group, sham emotional freedom technique group and control groups each consisted of 35 menopausal women.

Conditions in scope

  • Menopause

Interventions

  • Emotional freedom technique group (Behavioral) — Menopausal women in the emotional freedom technique group will be administered the emotional freedom technique by the researcher a total of 4 times at one week intervals.
  • Sham emotional freedom technique group (Behavioral) — Menopausal women in the sham emotional freedom technique group will be administered sham emotional freedom technique by the researcher a total of 4 times with one week intervals.

Who can join

Women only · Ages 45 Years to 59 Years · Accepts healthy volunteers.

Inclusion criteria

  • A person who has gone through menopause naturally,
  • No menstruation for the last one year,
  • Literate,
  • Not taking Hormone Replacement Therapy,
  • No oncologic disease,
  • No infection, wound, scar in the tapping areas,
  • Women who are able to communicate will be included in the study.

Exclusion criteria

  • One who has not gone through menopause naturally,
  • Illiterate,
  • Receiving Hormone Replacement Therapy,
  • Women with conditions such as infections, wounds, scars in the tapping areas.

Eligibility wording paraphrased from the public record. View the full criteria on ClinicalTrials.gov before contacting a site.

Where it’s happening

CityState / RegionFacilitySite status
Malatya Firat Family Health Center Unknown
Malatya Göztepe Family Health Center Unknown

Status & timeline

  • Overall status: Completed
  • Study type: Interventional
  • Phase: N/A
  • Start date: 2023-12-05
  • Primary completion: 2024-06-30
  • Last update posted: 2025-04-30
  • First posted: 2023-12-06

Lead sponsor: Kahramanmaras Sutcu Imam University (Other)

For trial site contact information, use the official record at ClinicalTrials.gov. Contact details change frequently and the public record is the source of truth.

Outcome measures

Primary outcomes

  • Determining the level of perimenopausal depression (The Perimenopausal Depression Scale will be administered to three groups of menopausal women on day one (first interview).)
    The scale was developed to rate the severity of perimenopausal depression symptoms. The scale consists of 12 items and five subscales related to energy, paranoid ideation, irritability, self-esteem, isolation, anxiety, somatic symptoms, sleep disturbance, weight, sexual interest, memory and concentration. All items of the scale are scored between 0 and 4. The lowest score that can be obtained from the…
  • Determining the level of perimenopausal depression (The Perimenopausal Depression Scale will be administered to three groups of menopausal women at the last interview (after the 4th intervention at one week interval).)
    The scale was developed to rate the severity of perimenopausal depression symptoms. The scale consists of 12 items and five subscales related to energy, paranoid ideation, irritability, self-esteem, isolation, anxiety, somatic symptoms, sleep disturbance, weight, sexual interest, memory and concentration. All items of the scale are scored between 0 and 4. The lowest score that can be obtained from the…
  • Determining quality of life (The Menopause Specific Quality of Life Scale will be administered to three groups of menopausal women on day one (first interview).)
    The Menopause Specific Quality of Life Scale assesses the quality of life of menopausal women. The scale consists of 29 Likert-type questions and 4 sub-domains: vasomotor, psychosocial, physical and sexual. The score for each question varies between 1 and 8. In scoring, a score of 1 indicates that the situation was not experienced, a score of 2 indicates that the…
  • Determining quality of life (The Menopause Specific Quality of Life Scale will be administered to three groups of menopausal women at the last interview (after the 4th intervention at one week interval).)
    The Menopause Specific Quality of Life Scale assesses the quality of life of menopausal women. The scale consists of 29 Likert-type questions and 4 sub-domains: vasomotor, psychosocial, physical and sexual. The score for each question varies between 1 and 8. In scoring, a score of 1 indicates that the situation was not experienced, a score of 2 indicates that the…
  • Assessment of menopausal symptoms (The Menopausal Symptoms Rating Scale will be administered to three groups of menopausal women on day one (first interview).)
    The Menopausal Symptoms Rating Scale measures the severity of menopausal symptoms. In the Likert-type scale consisting of a total of 11 items including menopausal complaints, there are "0= None", "1= Mild", "2= Moderate", "3= Severe" and "4= Very severe" options for each item. The total score of the scale is calculated based on the scores given for each item. The…

If you’re reading this trial because you have menopause symptoms now, you don’t have to wait for a trial to access evidence-based care. ClearedRx prescribes the same FDA-approved and compounded HRT products that have been studied in trials like this one for decades.

Important. Information from ClinicalTrials.gov as of May 8, 2026. Trial details (status, sites, contacts, eligibility, outcomes) change frequently — always check the official record at https://clinicaltrials.gov/study/NCT06158672 before contacting a site.

ClearedRx is not affiliated with this trial or its sponsor. We index public-domain ClinicalTrials.gov records to help patients find evidence-based context for menopause care decisions. ClearedRx itself is a telehealth menopause/HRT brand — we do not enroll patients in trials.